Correction to Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: A systematic review and meta-analysis [Hepatology, 61, (2015), 526-536], DOI: 10.1002/hep.27431;Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: A systematic review and meta-analysis

Hepatology

Volumn 61, Issue 2, 2015, Pages 526-536

  Berzigotti, Annalisa ^a,b   Reig, Maria ^a,b   Abraldes, Juan G ^a,b   Bosch, Jaime ^a,b   Bruix, Jordi ^a,b  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER PATIENT; DECOMPENSATED LIVER CIRRHOSIS; HUMAN; LIVER CELL CARCINOMA; META ANALYSIS; PORTAL HYPERTENSION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RISK ASSESSMENT; SURGICAL MORTALITY; SURVIVAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME; CARCINOMA, HEPATOCELLULAR; COMPLICATION; LIVER NEOPLASMS; MORTALITY;

CARCINOMA, HEPATOCELLULAR; HUMANS; HYPERTENSION, PORTAL; LIVER NEOPLASMS;

EID: 84921476595     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28351     Document Type: Erratum

References (37)

1. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-943.
2. Verslype C, Rosmorduc O, Rougier P. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7):vii41-vii48.
3. Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 2014;63:844-855.
4. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012 31;379:1245-1255.
5. Bruix J, Castells A, Bosch J, Feu F, Fuster J, Garcia-Pagan JC, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996;111:1018-1022.
6. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999;30:1434-1440.
7. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
8. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022.
9. Cucchetti A, Ercolani G, Vivarelli M, Cescon M, Ravaioli M, Ramacciato G, et al. Is portal hypertension a contraindication to hepatic resection? Ann Surg 2009;250:922-928.
10. Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 2008;134:1908-1916.
11. Forner A, Bruix J. East meets the West-portal pressure predicts outcome of surgical resection for hepatocellular carcinoma. Nat Clin Pract Gastroenterol Hepatol 2009;6:14-15.
12. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264-9.
13. Hayden JA, Cote P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 2006;144:427-437.
14. Hayden JA, van der Windt DA, Cartwright JL, Cote P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med 2013;158:280-286.
15. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 2007;28:105-114.
16. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
17. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-174.
18. Boleslawski E, Petrovai G, Truant S, Dharancy S, Duhamel A, Salleron J, et al. Hepatic venous pressure gradient in the assessment of portal hypertension before liver resection in patients with cirrhosis. Br J Surg 2012;99:855-863.
19. Capussotti L, Ferrero A, Vigano L, Muratore A, Polastri R, Bouzari H. Portal hypertension: contraindication to liver surgery? World J Surg 2006;30:992-999.
20. Giannini EG, Savarino V, Farinati F, Ciccarese F, Rapaccini G, Marco MD, et al. Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients. Liver Int 2013;33:1594-1600.
21. Hidaka M, Takatsuki M, Soyama A, Tanaka T, Muraoka I, Hara T, et al. Intraoperative portal venous pressure and long-term outcome after curative resection for hepatocellular carcinoma. Br J Surg 2012;99:1284-1289.
22. Llop E, Berzigotti A, Reig M, Erice E, Reverter E, Seijo S, et al. Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. J Hepatol 2012;56:103-108.
23. Ruzzenente A, Valdegamberi A, Campagnaro T, Conci S, Pachera S, Iacono C, et al. Hepatocellular carcinoma in cirrhotic patients with portal hypertension: is liver resection always contraindicated? World J Gastroenterol 2011;17:5083-5088.
24. Santambrogio R, Kluger MD, Costa M, Belli A, Barabino M, Laurent A, et al. Hepatic resection for hepatocellular carcinoma in patients with Child-Pugh's A cirrhosis: is clinical evidence of portal hypertension a contraindication? HPB (Oxford) 2013;15:78-84.
25. Bosch J, Abraldes JG, Berzigotti A, Garcia-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol 2009;6:573-582.
26. Ripoll C, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007;133:481-488.
27. Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet 2014;383:1749-61.
28. Qamar AA, Grace ND, Groszmann RJ, Garcia-Tsao G, Bosch J, Burroughs AK, et al. Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosis. Hepatology 2008;47:153-159.
29. Berzigotti A, Gilabert R, Abraldes JG, Nicolau C, Bru C, Bosch J, et al. Noninvasive prediction of clinically significant portal hypertension and esophageal varices in patients with compensated liver cirrhosis. Am J Gastroenterol 2008;103:1159-1167.
30. Berzigotti A, Seijo S, Arena U, Abraldes JG, Vizzutti F, Garcia-Pagan JC, et al. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology 2013;144:102-111.
31. Berzigotti A, Reig M, Abraldes JG, Bruix J, Bosch J, García-Pagán JC. Letter to the editor: "Value of transient elastography measured with FibroScan in predicting the outcome of hepatic resection for hepatocellular carcinoma". Ann Surg 2013 Nov 20. doi: 10.1097/SLA.0000000000000394. [Epub ahead of print].
32. Cescon M, Colecchia A, Cucchetti A, Peri E, Montrone L, Ercolani G, et al. Value of transient elastography measured with FibroScan in predicting the outcome of hepatic resection for hepatocellular carcinoma. Ann Surg 2012;256:706-712; discussion, 712-713.
33. Cescon M, Cucchetti A, Colecchia A, Ercolani G, Festi D, Pinna AD. Reply to letter: "Value of transient elastography measured with FibroScan in predicting the outcome of hepatic resection for hepatocellular carcinoma". Ann Surg 2013 Nov 20. doi: 10.1097/SLA.0000000000000393. [Epub ahead of print].
34. Cherqui D, Laurent A, Tayar C, Chang S, Van Nhieu JT, Loriau J, et al. Laparoscopic liver resection for peripheral hepatocellular carcinoma in patients with chronic liver disease: midterm results and perspectives. Ann Surg 2006;243:499-506.
35. Taura P, Fuster J, Mercadal J, Martinez-Palli G, Fondevila C, Blasi A, et al. The use of beta-adrenergic drugs improves hepatic oxygen metabolism in cirrhotic patients undergoing liver resection. J Hepatol 2010;52:340-347.
36. Burrel M, Reig M, Forner A, Barrufet M, de Lope CR, Tremosini S, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol 2012;56:1330-1335.
37. Malagari K, Pomoni M, Moschouris H, Bouma E, Koskinas J, Stefaniotou A, et al. Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc Intervent Radiol 2012;35:1119-1128.